Myrobalan Therapeutics Awarded a Grant from the National Multiple Sclerosis Society to Advance Development of MRO-002 in Multiple Sclerosis
Summary
The grant is being awarded through the National MS Societys Fast Forward program, an initiative that supports commercial organizations developing novel therapies and diagnostic tools for MS.MS is an unpredictable disease of the central nervous system (CNS), characterized by neuroinflammation and demyelination. "We believe that MRO-002 has the potential to promote myelin repair in neurodegenerative diseases, demyelinating disorders, and conditions involving recovery from CNS injury. "MRO-002 is an orally bioavailable, brain-penetrant, small molecule antagonist of GPR17, which serves as a block to myelin repair.Myrobalan Therapeutics is a preclinical stage biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies to reverse key pathologies underlying dysfunctions in the central nervous system (CNS) microenvironment in the setting of neurodegeneration and brain injury. Myrobalan applies deep knowledge of drug discovery and neurological processes underlying demyelination and neuroinflammation to create highly selective and brain-penetrant therapeutic candidates uniquely positioned for treating CNS conditions with significant unmet medical need. Myrobalan is committed to a transformed future in which patients with degenerative CNS conditions can access safe and effective medicines offering restorative potential.